BioSpace News Archive

Business

Cardiovascular Systems, Inc. to Host Earnings Conference Call on May 4, 2022

Cardiovascular Systems, Inc. plans to announce its operating results for the quarter ended March 31, 2022 before the market opens on Wednesday, May 4, 2022, and will host a conference call at 8:00 a.m. CT that day to discuss those results.

April 13, 2022
·
1 min read
Drug Development

NeoImmuneTech Demonstrates NT-I7’s Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine at AACR 2022

Pre-clinical studies demonstrate NT-I7’s potential to enhance anti-tumor responses in combination with compounds targeting multiple biological pathways.

April 13, 2022
·
4 min read
Business

Repligen to Report First Quarter 2022 Financial ResultsWebcast and Conference Call to Be Held Wednesday, April 27, 2022 at 8:30 a.m. EDT

Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2022 financial results on Wednesday, April 27, 2022.

April 13, 2022
·
2 min read
Lone Star Bio

Renibus Therapeutics Strengthens IP Position with Additional US Patent

Renibus Therapeutics® (“Renibus”), a clinical-stage biotech company focusing on the prevention and treatment of cardio-renal diseases, today announced that the United States Patent and Trademark Office (USPTO) has granted the addition of a new patent to its IP portfolio.

April 13, 2022
·
2 min read
Biotech Bay

Applied Molecular Transport Announces Publication in Tissue Barriers Providing Additional Insight into Company’s Proprietary Technology Platform

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, announced that new insights into the unique mechanism of action utilized by its oral biologic product candidates, including lead clinical programs AMT-101 and AMT-126, have been published in Tissue Barriers.

April 13, 2022
·
5 min read
Genetown

Fresenius Medical Care Launches My Reason® Campaign to Enroll Patients in Groundbreaking Renal-focused Genomic Registry

Fresenius Medical Care announced today that the company’s Global Medical Office has launched the My Reason® campaign to promote patient enrollment in the company’s kidney-focused genomics registry which was first introduced last year.

April 13, 2022
·
4 min read
Drug Development

Phosplatin Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of PT-112 for Thymoma and Thymic Carcinoma in Collaboration with National Cancer Institute

Phosplatin Therapeutics Inc. today announced the first patient has been treated in a Phase 2 clinical trial of the company’s lead therapeutic candidate, PT-112.

April 13, 2022
·
5 min read
Business

Autigen Announces Collaboration with Boehringer Ingelheim to Discover and Develop Novel Treatments for Hearing Loss

Autigen Announces Collaboration with Boehringer Ingelheim to Discover and Develop Novel Treatments for Hearing Loss.

April 13, 2022
·
3 min read
Drug Development

CG Oncology Presents Interim Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

CG Oncology Presents Interim Phase 2 Data with CG0070 in Combination with KEYTRUDA ® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin.

April 13, 2022
·
4 min read
FDA

Pear Therapeutics Receives Safer Technologies Program (STeP) Designation from FDA for Product Candidate to Treat Acute and Chronic Pain

Pear Therapeutics, Inc. today announced it has received Safer Technologies Program (STeP) for Medical Devices designation from the U.S. Food and Drug Administration (FDA) for Pear-010, a product candidate designed for the treatment of acute and chronic pain.

April 13, 2022
·
7 min read